Protagonist Therapeutics (PTGX) Announces FDA Granted Orphan Drug Designation for PTG-300 for Treatment of Beta-Thalassemia
Tweet Send to a Friend
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE